Browse Items (2 total)

• Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

  Tags 2019-nCoV, Coronavirus, COVID-19, R-Res&Pub, Trial, Vaccine Study
  Creator: the Oxford COVID Vaccine Trial Group
  Subject: Research
  Item Type: Publication
  Date Last Updated: 2021-02-19
  Description: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks.
• 

  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

  Tags 2019-nCoV, Coronavirus, COVID-19, R-Res&Pub, Vaccine Study
  Creator: the Oxford COVID Vaccine Trial Group
  Subject: Research
  Item Type: Publication
  Date Last Updated: 2020-12-08
  Description: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19…